What do we know about macrolides immunomodulatory therapeutic potential in respiratory disease in 2023

被引：0
|
作者：
Godinho, Daniela [1 ]
Freixa, Marta [2 ]
Froes, Filipe [1 ]
机构：
[1] Ctr Hosp Univ Lisboa Norte, Thorax Dept, Lisbon, Portugal
[2] Ctr Hosp Univ Lisboa Norte, Hosp Pulido Valente, Internal Med, Lisbon, Portugal
来源：
PULMONOLOGY | 2024年 / 30卷 / 06期
关键词：
AZITHROMYCIN;
D O I：
10.1016/j.pulmoe.2024.02.001
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：509 / 511
页数：3
相关论文
共 6 条
  • [1] Asthma and COVID-19: What do we know?
    Sarioglu, Nurhan
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2020, 68 (02): : 141 - 147
  • [2] Immunomodulatory effects of macrolide antibiotics in respiratory disease: Therapeutic implications for asthma and cystic fibrosis
    Sharma S.
    Jaffe A.
    Dixon G.
    Pediatric Drugs, 2007, 9 (2) : 107 - 118
  • [3] Improving our forecasts for trachoma elimination: What else do we need to know?
    Pinsent, Amy
    Gambhir, Manoj
    PLOS NEGLECTED TROPICAL DISEASES, 2017, 11 (02):
  • [4] What the dental practitioner needs to know about pharmaco-therapeutic modalities of COVID-19 treatment: A review
    Dar-Odeh, Najla
    Elsayed, Shadia
    Babkair, Hamzah
    Abu-Hammad, Shaden
    Althagafi, Nebras
    Bahabri, Rayan
    Eldeen, Yasmin Salah
    Aljohani, Wejdan
    Abu-Hammad, Osama
    JOURNAL OF DENTAL SCIENCES, 2021, 16 (03) : 806 - 816
  • [5] Cystic fibrosis. Current therapeutic strategies do not prevent respiratory disease: Early therapeutic interventions are needed in infants screened for cystic fibrosis!
    Reix, P.
    Bellon, G.
    ARCHIVES DE PEDIATRIE, 2011, 18 (02): : 125 - 127
  • [6] Phosphodiesterase Inhibition as a Therapeutic Strategy for Chronic Obstructive Pulmonary Disease: Where We Have Been and What Lies Ahead
    Hanania, Nicola A.
    Celli, Bartolome R.
    CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, 2025, 12 (01): : 82 - 92
1